A multiplatform approach identifies miR-152-3p as a common epigenetically regulated onco-suppressor in prostate cancer targeting TMEM97

被引：0

作者：

João Ramalho-Carvalho

Céline S. Gonçalves

Inês Graça

David Bidarra

Eva Pereira-Silva

Sofia Salta

Maria Inês Godinho

Antonio Gomez

Manel Esteller

Bruno M. Costa

Rui Henrique

Carmen Jerónimo

机构：

[1] Cancer Biology & Epigenetics Group – Research Center (CI-IPOP),Biomedical Sciences Graduate Program

[2] Portuguese Oncology Institute of Porto (IPO Porto),Life and Health Sciences Research Institute (ICVS), School of Medicine

[3] Cancer Epigenetics and Biology Program,ICVS/3B’s

[4] Bellvitge Biomedical Research Institute, PT Government Associate Laboratory, Braga/Guimarães

[5] Institute of Biomedical Sciences Abel Salazar– University of Porto (ICBAS-UP),Department of Immunology

[6] University of Minho,Physiological Sciences Department, School of Medicine and Health Sciences

[7] University of Minho,Department of Pathology

[8] Portuguese Oncology Institute of Porto,Department of Pathology and Molecular Immunology

[9] Institucio Catalana de Recerca i Estudis Avançats (ICREA),Present Address: Division of Oncogenomics

[10] University of Barcelona (UB),Present Address: Gene Regulation, Stem Cells and Cancer Programme, Centre for Genomic Regulation (CRG)

[11] Portuguese Oncology Institute of Porto,undefined

[12] Institute of Biomedical Sciences Abel Salazar– University of Porto (ICBAS-UP),undefined

[13] Netherlands Cancer Institute,undefined

[14] The Barcelona Institute of Science and Technology,undefined

来源：

Clinical Epigenetics | 2018年 / 10卷

关键词：

miR-152-3p; Prostate cancer; Cell cycle; DNA methylation; CRISPR;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用